Ascentage Pharma Launches New Phase I Blood Cancer Trial That Could Shape Its Pipeline Outlook

Ascentage Pharma Group International (HK:6855) announced an update on their ongoing clinical study.

The Phase I study titled “A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies” will test a new oral cancer drug in hard‑to‑treat blood cancers. It aims to find a safe dose, early signs of benefit, and a path toward later phase trials that could expand Ascentage Pharma Group Inc.’s pipeline.

The treatment under review is APG-3288, an experimental oral drug taken once daily in 28‑day cycles. It is designed for patients whose blood cancers, such as CLL/SLL, DLBCL, MCL, WM, MZL, and FL, have come back or not responded to past therapies.

This is an interventional Phase I trial that is non‑randomized and open label, so all patients know they receive APG-3288 and there is no placebo group. The study follows a sequential two‑part model, starting with dose escalation to define the best dose, then moving into dose expansion to test that dose in specific cancer types with treatment benefit as the main goal.

Part 1 will escalate doses of APG-3288 to pin down the maximum tolerated dose and the recommended dose for Phase 2. Part 2 will then enroll more patients at selected doses and in chosen indications to better judge safety and early efficacy before any larger, later stage studies are planned.

The study was first submitted on 2026‑02‑01 and is listed as not yet recruiting, which means sites are preparing to open but patients are not yet enrolled. The last update on 2026‑02‑19 signals that planning and regulatory steps are active, and investors should watch for future postings of start of enrollment, primary completion, and final completion dates as key risk and timing markers.

For Ascentage Pharma (HK:6855), this early‑stage trial adds another shot on goal in blood cancer, where large players like AbbVie and Johnson & Johnson already generate strong revenue. A clean safety profile and any early efficacy signals could lift sentiment and support valuation, while delays or safety issues may pressure the stock in a crowded and competitive lymphoma and leukemia space.

The APG-3288 study is currently in the setup phase and remains active on the registry, with further details and future updates available on the ClinicalTrials portal.

To learn more about HK:6855’s potential, visit the Ascentage Pharma Group International drug pipeline page.